10:13 AM EDT, 05/23/2025 (MT Newswires) -- The European Medicines Agency's Committee for Medicinal Products for Human Use said Friday it recommended an extension of therapeutic indication for Beigene's ( ONC ) cancer drug Tevimbra.

Tevimbra is already authorized in the EU, the committee said, with indications for non-small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma, and oesophageal squamous cell carcinoma.

Price: 240.05, Change: +1.29, Percent Change: +0.54